Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Value of Device-Gathered Data to Regulatory Agencies

Posted by Matt Breese on Jun 5, 2018

While physicians may be the obvious stakeholder to benefit from the data gathered from wearable and handheld drug-administration devices, regulatory bodies also are realizing their value, AIS Health reported.
 
In recent years, both FDA and the European Medicines Agency are warming to the use of real-world evidence (RWE) during the regulatory-approval process, according to John J. Doyle, senior vice president and general manager, real-world and analytic services, IQVIA.
 
Read More

Topics: Industry Trends, Data & Analytics

MMIT Reality Check on Chronic Lymphocyctic Leukemia

Posted by Matt Breese on May 31, 2018

According to our recent payer coverage analysis for CLL treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Atopic Dermatitis (May 2018)

Posted by Matt Breese on May 31, 2018

According to our recent payer coverage analysis for atopic dermatitis, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Radar On Market Access: Pharma Faces Limits When Providing Payers Drug Information

Posted by Matt Breese on May 31, 2018

Payers increasingly are looking to pharma to provide evidence that a drug will provide value, yet some restrictions still limit what information manufacturers actually can provide to payers, AIS Health reported.
 
"Generally, drug companies cannot talk to stakeholders about unapproved products outside of 'coming soon' ads and scientific exchange," says Ernest Voyard, a director in Avalere Health’s regulatory strategy practice. "However, FDA issued a draft guidance last year that included direction for conversations with payers that included safe harbors for conversations about investigational products, recognizing a need for payors to plan for the future."  
 
Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: Express Scripts Inks Deal with Praluent Manufacturers

Posted by Matt Breese on May 29, 2018

Express Scripts Holding Co. has struck a deal with the manufacturers of Praluent (alirocumab), one of two pricey PCSK9 inhibitors on the market, that will give the PBM a lower net price on the drug in exchange for streamlined patient access and an exclusive spot on the Express Scripts national formulary, AIS Health reported.
 
The pact, unveiled May 1, comes after Regeneron and Sanofi announced in March that they would lower the net price of Praluent for payers willing to reduce access barriers for appropriate patients.
 
Read More

Topics: Industry Trends, Market Access, Provider

Radar On Market Access: Drug Cost Transparency Service

Posted by Matt Breese on May 24, 2018

Blue Shield of California has unveiled a program designed to show doctors lower-cost alternative medications and enable them to compare prices and make prescribing changes while meeting with patients in their offices, AIS Health reported.
 
The new Gemini Drug-Cost Transparency Service, which is developed by Gemini Health, LLC, taps into providers' existing electronic health record (EHR) systems. 
 
Read More

Topics: Data & Analytics, Payer

Radar On Market Access: Managed Care Strategies for Specialty Pharmaceuticals

Posted by Matt Breese on May 22, 2018

A survey by EMD Serono, Inc. revealed that managing oncology drugs and services remains the top challenge for health plans, tied with determining the value of specialty drugs and ensuring clinically appropriate use of specialty therapies.
 
Released at the end of April, the 14th edition of the EMD Serono Specialty Digest: Managed Care Strategies for Specialty Pharmaceuticals is based on survey responses from 59 commercial health plans representing more than 76 million covered lives. 
 
Read More

Topics: Industry Trends, Market Access, Data & Analytics

MMIT Reality Check on Psoriasis (Q2 2018)

Posted by Matt Breese on May 18, 2018

According to our recent payer coverage analysis for psoriasis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Radar On Market Access: American Patients First Blueprint

Posted by Matt Breese on May 17, 2018

After more than a year of promising action to counter the high costs of prescription drugs, the Trump administration on May 11 unveiled its American Patients First blueprint aimed at lowering medication prices and reducing costs for consumers, AIS Health reported.
 
Steve Wojcik, vice president, public policy, National Business Group on Health, says the blueprint "generally followed what was in the Administration’s proposal budget, by and large."
 
Read More

Topics: Industry Trends, Provider

Radar On Market Access: Outcomes-Based Drug Pricing

Posted by Matt Breese on May 15, 2018

While outcomes-based contracts for prescription drugs are a continual hot topic in the health care industry, experts who spoke on a panel May 1 at the World Health Care Congress cited several barriers that are keeping these contracts from proliferating widely: chiefly, not enough reliable data and regulatory issues such as the federal antikickback statute.
 
"The beautiful thing about value-based contracts is we are basically putting the patient at the center of everything," said Enrique A. Conterno, senior vice president of Eli Lilly and Co.
 
Read More

Topics: Industry Trends, Market Access, Payer